NYSE:IMVIMV Stock Price, Forecast & News

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMV stock has increased by 111.8% and is now trading at $5.04.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMV.

IMV is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for IMV.

Imv Inc (NYSE:IMV) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.03. The firm earned $0.05 million during the quarter, compared to analyst estimates of $0.04 million.
View IMV's earnings history.

8 brokers have issued 1-year price targets for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's share price to reach $8.14 in the next twelve months. This suggests a possible upside of 61.6% from the stock's current price.
View analysts' price targets for IMV.

Press coverage about IMV stock has trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMV earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about IMV.

Some companies that are related to IMV include Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), Nkarta (ANNX), Trillium Therapeutics (TRIL), iShares Diversified Alternatives Trust (ALT), PureTech Health (PRTC), Altimmune (ALT), Oxford BioMedica (OXB), Aptose Biosciences (APS), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Inventiva (IVA), CEL-SCI (CVM) and Pfenex (PFNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania R.E.I.T. (PEI), Cannabics Pharmaceuticals (CNBX), DHT (DHT), OrganiGram (OGI) and BioNano Genomics (BNGO).

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

IMV's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.10%), Creative Planning (0.08%), Scotia Capital Inc. (0.05%) and Vident Investment Advisory LLC (0.02%).

IMV stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can.

IMV stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Scotia Capital Inc., and Vident Investment Advisory LLC.

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMV stock can currently be purchased for approximately $5.04.

IMV has a market capitalization of $310.97 million.

The company can be reached via phone at (902) 492-1819.